Literature DB >> 15967672

Surgery for right ventricle to pulmonary artery conduit obstruction: risk factors for further reoperation.

Siamak Mohammadi1, Emre Belli, Ivo Martinovic, Lucile Houyel, André Capderou, Jérome Petit, Claude Planché, Alain Serraf.   

Abstract

OBJECTIVE: To identify the surgical approaches and risk factors which influence longevity of right ventricle to pulmonary artery (RV-PA) conduits following first reoperation for obstruction.
METHODS: Between January 1993 and August 2003, 114 patients underwent 141 reoperations for RV-PA conduit obstruction. Diagnoses included 'Truncus Arteriosus' (n=52), 'Pulmonary atresia/Tetralogy of fallot' (n=39), 'Double outlet right ventricle' (n=10), 'Transposition of great arteries, VSD, and pulmonary atresia' (n=9), and the 'Ross operation' (n=4). All patients had undergone a previous biventricular repair. The first reoperation for conduit obstruction was performed in 112 hospital survivors by: total conduit replacement (Group A, n=73) with valved (homograft=10 and xenograft=54) or non-valved (n=9) conduit, and patch enlargement of the obstructed RV outflow tract with preservation of the posterior and sides of the conduit wall after removing of the fibrocalcific peel and degenerated valve (Group B, n=39). Mean age at first reoperation was 8.8+/-6.7 and 7.5+/-5.3 years in patients of groups A and B, respectively. Seven patients in Group A and 18 in Group B required a second reoperation and two patients in Group B a third reoperation.
RESULTS: There were two hospital deaths and no late deaths. Mean follow-up was 5.8+/-3.2 years. Risk factors for second reoperation by univariate analysis were: homograft conduit use (P=0.004), Group B surgical approach (P=0.0001), higher RV-PA systolic pressure gradient at discharge (P=0.02), and age <5-years-old (P=0.01). Multivariate analysis showed that inclusion in Group B and younger age (<5-years-old) at repair were independent risk factors for second reoperation. Group B surgical approaches had higher RV-PA systolic pressure gradient at discharge (P=0.02) and required more PA bifurcation repair at the time of second reoperation (P=0.05). Freedom from second reoperation for conduit obstruction was significantly higher in Group A patients at 5 and 8 years (P<0.04) and those with xenografts rather than homograft (P=0.04).
CONCLUSIONS: Our results support the optimal surgical approach for RV-PA conduit obstruction is total replacement with a xenograft. RV outflow reconstruction by other techniques without complete dissection of PA bifurcation does not completely relieve the stenosis and could cause early restenosis. Higher systolic gradients at discharge and younger age at first reoperation are predictors of earlier reoperation.

Entities:  

Mesh:

Year:  2005        PMID: 15967672     DOI: 10.1016/j.ejcts.2005.04.014

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  12 in total

1.  "Baby Heart Project": the Italian project for accreditation and quality management in pediatric cardiology and cardiac surgery.

Authors:  Sonia B Albanese; Lucio V Zannini; Gianluigi Perri; Giancarlo Crupi; Bruno Turinetto; Giacomo Pongiglione
Journal:  Pediatr Cardiol       Date:  2014-06-01       Impact factor: 1.655

2.  The Effects of Pulmonary Valve Replacement for Severe Pulmonary Regurgitation on Exercise Capacity and Cardiac Function.

Authors:  Jason G Ho; Marcus S Schamberger; Roger A Hurwitz; Tiffanie R Johnson; Lauren E Sterrett; Eric S Ebenroth
Journal:  Pediatr Cardiol       Date:  2015-03-10       Impact factor: 1.655

3.  Management after childhood repair of tetralogy of fallot.

Authors:  Jamil Aboulhosn; John S Child
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-12

4.  Percutaneous balloon dilation of Carpentier-Edwards porcine-valved right ventricle-to-pulmonary artery conduits.

Authors:  Amanda C Hall; Daniel E Miga; Glenn T Leonard; Hongyue Wang; Rae-Ellen Kavey; George M Alfieris
Journal:  Pediatr Cardiol       Date:  2012-12-11       Impact factor: 1.655

5.  Expanded polytetrafluoroethylene-valved conduit with bulging sinuses for right ventricular outflow tract reconstruction in adults.

Authors:  Yosuke Takahashi; Yasushi Tsutsumi; Osamu Monta; Yasuyuki Kato; Keitaro Kohshi; Tomohiko Sakamoto; Hirokazu Ohashi; Takako Miyazaki; Masaaki Yamagishi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2010-01-09

6.  Right ventricle to pulmonary artery conduit augmentation compared with replacement in young children.

Authors:  Justin P V Zachariah; Frank A Pigula; John E Mayer; Doff B McElhinney
Journal:  Ann Thorac Surg       Date:  2009-08       Impact factor: 4.330

7.  Early systemic cellular immune response in children and young adults receiving decellularized fresh allografts for pulmonary valve replacement.

Authors:  Anneke Neumann; Samir Sarikouch; Thomas Breymann; Serghei Cebotari; Dietmar Boethig; Alexander Horke; Philipp Beerbaum; Mechthild Westhoff-Bleck; Harald Bertram; Masamichi Ono; Igor Tudorache; Axel Haverich; Gernot Beutel
Journal:  Tissue Eng Part A       Date:  2014-01-24       Impact factor: 3.845

8.  Midterm results of homografts in pulmonary position: a retrospective single-center study.

Authors:  Javid Raja; Sabarinath Menon; Sowmya Ramanan; Sudip Dutta Baruah; Arun Gopalakrishnan; Baiju Sasi Dharan
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2020-11-23

9.  Injectable tissue engineered pulmonary heart valve implantation into the pig model: A feasibility study.

Authors:  Franziska Schlegel; Aida Salameh; Katja Oelmann; Michelle Halling; Stefan Dhein; Friedrich W Mohr; Pascal M Dohmen
Journal:  Med Sci Monit Basic Res       Date:  2015-06-24

10.  Pulmonary valve replacement after right ventricular outflow tract reconstruction with homograft vs Contegra®: a case control comparison of mortality and morbidity.

Authors:  Nicolas Poinot; Jean-Francois Fils; Hélène Demanet; Hugues Dessy; Dominique Biarent; Pierre Wauthy
Journal:  J Cardiothorac Surg       Date:  2018-01-17       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.